Luciana Curtolo de Barros

Luciana Curtolo de Barros

Auto-generated profile, based on publicly available information

Luciana Curtolo de Barros

Center for the Study of Venoms and Venomous Animals (CEVAP), São Paulo State University (UNESP - Univ Estadual Paulista), Botucatu, SP Brazil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2009 in Journal of Toxicology and Environmental Health, Part B
Verified
Journal Article
Closed access
LBL. C. Barros
L. C. Barros
Rui Seabra Ferreira JuniorRui Seabra Ferreira Junior
Rui Seabra Ferreira Junior
SBS. R. C. S. Barraviera
S. R. C. S. Barraviera
HSH. O. Stolf
H. O. Stolf
ITI. A. Thomazini-Santos
I. A. Thomazini-Santos
BBBenedito Barraviera
Benedito Barraviera
Fibrin sealant, a widely available tissue adhesive, has been used since 1940 in a variety of clinical applications. Commercially available fibrin sealant products are synthesized from bovine thrombin and human fibrinogen, which may transmit infectious diseases, and recipients may also develop antibodies against bovine thrombin. Bearing these disadvantages in mind, a new fibrin sealant was developed in 1989 by a group of researchers from the Center for the Study of Venoms and Venomous Animals, in Sao Paulo State, Brazil. The main purpose was to produce an adhesive fibrin without using human blood, to avoid transmitting infectious diseases. The components of this novel sealant were extracted from large animals and a serine proteinase extracted from Crotalus durissus terrificus snake venom. The applicability of this sealant was tested in animals and humans with beneficial results. The new fibrin sealant can be a useful tool clinically due to its flexibility and diversity of applications. This sealant is a biological and biodegradable product that (1) does not produce adverse reactions, (1) contains no human blood, (3) has a good adhesive capacity, (4) gives no transmission of infectious diseases, and (5) may be used as an adjuvant in conventional suture procedures. The effectiveness of this new fibrin sealant is reviewed and its development and employment are described.

4 April 2017 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
PDF file
Rui Seabra Ferreira JuniorRui Seabra Ferreira Junior
Rui Seabra Ferreira Junior
LBLuciana Curtolo de Barros
Luciana Curtolo de Barros
LALuciana Patrícia Fernandes Abbade
Luciana Patrícia Fernandes Abbade
SBSilvia Regina Catharino Sartori Barraviera
Silvia Regina Catharino Sartori Barraviera
MSMaria Regina Cavariani Silvares
Maria Regina Cavariani Silvares
BBBenedito Barraviera
Benedito Barraviera
Hemostatic and adhesive agents date back to World War II, when homologous fibrin sealant came onto scene. Considering that infectious diseases can be transmitted via human blood, a new heterologous fibrin sealant was standardized in the 1990s. Its components were a serine protease (a thrombin-like enzyme) extracted from the venom of Crotalus durissus terrificus snakes and a fibrinogen-rich cryoprecipitate extracted from the blood of Bubalus bubalis buffaloes. This new bioproduct has been used as a coagulant, sealant, adhesive and recently as a candidate scaffold for mesenchymal stem cells and bone and cartilage repair. This review discusses the composition of a new heterologous fibrin sealant, and cites published articles related to its preclinical applications aiming at repairing nervous system traumas and regenerating bone marrow. Finally, we present an innovative safety trial I/II that found the product to be a safe and clinically promising candidate for treating chronic venous ulcers. A multicenter clinical trial, phase II/III, with a larger number of participants will be performed to prove the efficacy of an innovative biopharmaceutical product derived from animal venom.

1 January 2011 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
PDF file
LBLc Barros
Lc Barros
ASAm Soares
Am Soares
FCFl Costa
Fl Costa
VRVeridiana Rodrigues
Veridiana Rodrigues
AFAL Fuly
AL Fuly
Rui Seabra Ferreira JuniorRui Seabra Ferreira Junior
Rui Seabra Ferreira Junior
Gyroxin, a thrombin-like enzyme isolated from Crotalus durissus terrificus venom and capable of converting fibrinogen into fibrin, presents coagulant and neurotoxic activities. The aim of the present study was to evaluate such coagulant and toxic properties. Gyroxin was isolated using only two chromatographic steps - namely gel filtration (Sephadex G-75) and affinity (Benzamidine Sepharose 6B) - resulting in a sample of high purity, as evaluated by RP-HPLC C2/C18 and electrophoretic analysis that showed a molecular mass of 30 kDa. Gyroxin hydrolyzed specific chromogenic substrates, which caused it to be classified as a serine proteinase and thrombin-like enzyme. It was stable from pH 5.5 to 8.5 and inhibited by Mn²+, Cu²+, PMSF and benzamidine. Human plasma coagulation was more efficient at pH 6.0. An in vivo toxicity test showed that only behavioral alterations occurred, with no barrel rotation. Gyroxin was not able to block neuromuscular contraction in vitro, which suggests that its action, at the studied concentrations, has no effect on the peripheral nervous system.

15 August 2012 in Journal of Toxicology and Environmental Health, Part A
Verified
Journal Article
Closed access
ESEduardo Saad
Eduardo Saad
LBLuciana Curtolo Barros
Luciana Curtolo Barros
NBNatalia Biscola
Natalia Biscola
Daniel Carvalho PimentaDaniel Carvalho Pimenta
Daniel Carvalho Pimenta
SBSilvia R. C. S. Barraviera
Silvia R. C. S. Barraviera
Rui Seabra Ferreira JuniorRui Seabra Ferreira Junior
Rui Seabra Ferreira Junior
The venom of Bothrops jararaca is composed of complex mixture of molecules, mainly lectins, metalloproteinases, serinoproteinases, desintegrins, phospholipases, and peptides. This composition may vary according to the snake's age, gender, and region of origin. The aim of the was to determine individual variation in Bothrops jararaca venom in the Botucatu region, Sao Paulo State, Brazil, by means of enzymatic, biochemical, and pharmacological characterization, utilizing in vitro tests and biological assays. The activities were compared with those of Brazilian Reference Venom (BRV). Protein concentration varied between adult and juvenile groups. The electrophoretic profiles were similar, with molecular masses ranging between 25 and 50 kD, but with intraspecific variations. Reverse-phase high-performance liquid chromatography (RP-HPLC) revealed protein concentration differences. Coagulant activity did not differ significantly among adult groups, but there was a large variation between juvenile venom and BRV, which coagulated more extensively. Venoms from adults displayed greater hemorrhagic activity, especially in males recently obtained from the wild. In contrast, juveniles kept in captivity and adult males showed higher values. Edematogenic activity displayed an increase in edema in all groups. At the mean lethal dose (LD₅₀), toxicity varied significantly between groups, with venom from captive females being threefold more toxic than juvenile venom. Data illustrate the intra- and interspecific complexity that occurs in snake venoms, which may be attributed to ontogenetic, sexual, and environmental factors that affect variability in Bothrops jararaca venom. Further, it is proposed that Brazilian public health authorities document the constitution of pooled venom employed in the immunization of serum-producing animals due to this variability in venom properties. Given the large Brazilian territory, this variability requires regional monitoring and evaluation of the efficacy of bothropic antivenom in treatment of snakebite and consequent permanent sequelae observed.

24 November 2015 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
PDF file
GBGustavo A. C. Barros
Gustavo A. C. Barros
APAndréia Pereira
Andréia Pereira
LBLuciana C. Barros
Luciana C. Barros
AJAirton Lourenço Jr
Airton Lourenço Jr
SCSueli A. Calvi
Sueli A. Calvi
Rui Seabra Ferreira JuniorRui Seabra Ferreira Junior
Rui Seabra Ferreira Junior
American visceral leishmaniasis is caused by the intracellular parasite Leishmania (L.) infantum chagasi, and transmitted by the sand fly Lutzomyia longipalpis. Since treatment is based on classical chemotherapeutics with significant side effects, the search for new drugs remains the greatest global challenge. Thus, this in vitro study aimed to evaluate the leishmanicidal effect of Crotalus durissus terrificus venom fractions on promastigote and amastigote forms of Leishmania (L.) infantum chagasi.

28 November 2017 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
PDF file
LOLaudicéia Alves de Oliveira
Laudicéia Alves de Oliveira
Rui Seabra Ferreira JuniorRui Seabra Ferreira Junior
Rui Seabra Ferreira Junior
BBBenedito Barraviera
Benedito Barraviera
FCFrancilene Capel Tavares de Carvalho
Francilene Capel Tavares de Carvalho
LBLuciana Curtolo de Barros
Luciana Curtolo de Barros
Daniel Carvalho PimentaDaniel Carvalho Pimenta
Daniel Carvalho Pimenta
Classically, Crotalus durissus terrificus (Cdt) venom can be described, according to chromatographic criteria, as a simple venom, composed of four major toxins, namely: gyroxin, crotamine, crotoxin and convulxin. Crotoxin is a non-covalent heterodimeric neurotoxin constituted of two subunits: an active phospholipase A2 and a chaperone protein, termed crotapotin. This molecule is composed of three peptide chains connected by seven disulfide bridges. Naturally occurring variants/isoforms of either crotoxin or crotapotin itself have already been reported. The crude Cdt venom was separated by using RP-HPLC and the toxins were identified by mass spectrometry (MS). Crotapotin was purified, reduced and alkylated in order to separate the peptide chains that were further analyzed by mass spectrometry and de novo peptide sequencing. The RP-HPLC profile of the isolated crotapotin chains already indicated that the α chain would present isoforms, which was corroborated by the MS and tandem mass spectrometry analyses. It was possible to observe that the Cdt crotapotin displays a preferred amino acid substitution pattern present in the α chain, at positions 31 and 40. Moreover, substitutions could also be observed in β and γ chains (one for each). The combinations of these four different peptides, with the already described chains, would produce ten different crotapotins, which is compatible to our previous observations for the Cdt venom.